SOPHiA GENETICS CSO granted options and RSUs
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported equity compensation awards and corrected prior ownership data.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4/A
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported equity compensation awards and corrected prior ownership data. He received a grant of 82,335 share options with a $5.04 exercise price expiring on April 2, 2036, plus 56,468 RSUs. The Form 4/A updates his beneficial ownership to 148,854 ordinary shares after these awards, amending an earlier filing that understated this amount.
Insider Trade Summary
Grant/Award: 138,803 shares
Grant/Award
2 txns
Insider
Puylaert Kevin
Role
Chief Sales Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 82,335 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares | 56,468 | $0.00 | $0.00 |
Holdings After Transaction:
Share Option (Right to Buy) — 82,335 contracts (Direct);
Ordinary Shares — 148,854 shares (Direct)
Footnotes (3)
- F1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
- F2. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 56,468 ordinary shares due to an inadvertent error. The correct amount is 148,854 ordinary shares.
- F3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Key Figures
Option grant size: 82,335 options
Option exercise price: $5.04 per share
Option expiration: April 2, 2036
+5 more
8 metrics
Option grant size
82,335 options
Share Option (Right to Buy) granted on April 2, 2026
Option exercise price
<money>$5.04</money> per share
Conversion or exercise price for option grant
Option expiration
<date>April 2, 2036</date>
Expiration date of share option grant
RSU grant size
56,468 RSUs
Restricted stock unit grant on April 2, 2026
Post-award share holdings
148,854 ordinary shares
Beneficially owned following reported transactions
Initial RSU vesting
25% on April 2, 2027
First vesting tranche for RSU grant
Remaining RSU vesting period
Through April 2, 2030
RSUs vest quarterly after initial tranche
Option vesting schedule
25% by April 2, 2027; rest monthly to 2030
Vesting for share option grant
Key Terms
restricted stock unit ("RSU"), 2021 Equity Incentive Plan, share option, beneficially owned, +1 more
5 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
2021 Equity Incentive Plan financial
"grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right"
beneficially owned financial
"correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction)"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
vest financial
"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did SOPHiA GENETICS (SOPH) disclose for Kevin Puylaert?
Kevin Puylaert reported equity awards, not open-market trades. He received 82,335 share options at a $5.04 exercise price and 56,468 restricted stock units, increasing his reported beneficial ownership to 148,854 ordinary shares after these compensation-related grants.
What are the key terms of Kevin Puylaert’s option grant at SOPHiA GENETICS (SOPH)?
The grant covers 82,335 share options with a $5.04 exercise price. Twenty-five percent vest on April 2, 2027, with the remainder vesting in equal monthly installments through April 2, 2030, and the options expire on April 2, 2036.
How do Kevin Puylaert’s RSUs at SOPHiA GENETICS (SOPH) vest?
He received 56,468 restricted stock units under the 2021 Equity Incentive Plan. Twenty-five percent of the RSUs vest on April 2, 2027, and the remaining 75% vest in equal quarterly installments through April 2, 2030, contingent on continued service.
What correction does this Form 4/A make for SOPHiA GENETICS (SOPH)?
The Form 4/A corrects the previously reported beneficial ownership in Column 5. An earlier filing showed 56,468 ordinary shares; this amendment states the correct amount is 148,854 ordinary shares following the reported equity awards to Kevin Puylaert.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates